<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30194145</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>14</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1791-7530</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>38</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Anticancer research</Title>                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>Pax-5 Inhibits Breast Cancer Proliferation Through MiR-215 Up-regulation.</ArticleTitle>            <Pagination>                <MedlinePgn>5013-5026</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.12820</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">In breast cancer, Pax-5 promotes pro-epithelial features and suppresses malignant cancer processes. However, the molecular mechanism of this antitumor activity remains largely unknown. This study aimed to identify the cellular roles of Pax-5-regulated miRNAs in breast cancer progression.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">After transient transfection of Pax-5 in MDA-MB-231 breast cancer cells, Pax-5-regulated miRNA expression was examined by next-generation sequencing. The identified Pax-5-regulated miRNAs were then validated by qRT-PCR and examined for the roles they play in breast cancer cells.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Pax-5 was shown to be an effective modulator of miR-215-5p and its target genes. MiR-215 inhibited cell proliferation and migration of breast cancer cells, but not cell invasion. More importantly, Pax-5-induced suppression of cancer cell proliferation and migration was found to be miR-215-dependent. Interestingly, miR-215 profiling in clinical tumor samples showed that miR-215 expression was lower in cancer tissues in comparison to healthy controls.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Pax-5 reduces breast cancer proliferation and migration through up-regulation of the tumor suppressor miR-215. This result supports the use of miR-215 as a prognostic marker for breast cancer.</AbstractText>                <CopyrightInformation>CopyrightÂ© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Leblanc</LastName>                    <ForeName>Nicolas</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, University of Moncton, Moncton, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Atlantic Cancer Research Institute, Moncton, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Harquail</LastName>                    <ForeName>Jason</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, University of Moncton, Moncton, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Atlantic Cancer Research Institute, Moncton, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Crapoulet</LastName>                    <ForeName>Nicolas</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, University of Moncton, Moncton, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Atlantic Cancer Research Institute, Moncton, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ouellette</LastName>                    <ForeName>Rodney J</ForeName>                    <Initials>RJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, University of Moncton, Moncton, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Atlantic Cancer Research Institute, Moncton, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Robichaud</LastName>                    <ForeName>Gilles A</ForeName>                    <Initials>GA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, University of Moncton, Moncton, Canada gilles.robichaud@umoncton.ca.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Atlantic Cancer Research Institute, Moncton, Canada.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Greece</Country>            <MedlineTA>Anticancer Res</MedlineTA>            <NlmUniqueID>8102988</NlmUniqueID>            <ISSNLinking>0250-7005</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C553667">MIRN215 microRNA, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D051757">PAX5 Transcription Factor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C497281">PAX5 protein, human</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051757" MajorTopicYN="N">PAX5 Transcription Factor</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015854" MajorTopicYN="Y">Up-Regulation</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">EMT/MET</Keyword>            <Keyword MajorTopicYN="N">Pax-5</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">miR-215-5p</Keyword>            <Keyword MajorTopicYN="N">miRNA</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30194145</ArticleId>            <ArticleId IdType="pii">38/9/5013</ArticleId>            <ArticleId IdType="doi">10.21873/anticanres.12820</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>